Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.32 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | PPIA | P62937 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084957 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1TSHRKMT2ASIGMAR1 | |
| SCHEMBL2084429 | 0.90 | MEN1 (0.38) | MEN1ALDH1A1TSHRKMT2ASIGMAR1 | |
| SCHEMBL14282561 | 0.83 | GRIN2B (0.35) | ALDH1A1EPHX1 | |
| SCHEMBL1949227 | 0.83 | GRIN2B (0.35) | ALDH1A1EPHX1 | |
| SCHEMBL2084118 | 0.79 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL12764361 | 0.79 | CTSK (0.33) | — | |
| SCHEMBL2084495 | 0.79 | PREP (0.45) | — | |
| SCHEMBL2077954 | 0.78 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL18410164 | 0.78 | L3MBTL1 (0.32) | DRD2HCRTR2PPIAL3MBTL1 | |
| SCHEMBL18365906 | 0.77 | GAA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| WO-2023064991-A1 | PROCESS FOR PREPARING BICYCLIC GLYCINE-PROLINE COMPOUNDS AND MONOCYCLIC GLYCINE-PROLINE INTERMEDIATES THEREOF | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-04-27 | — | — | WO | disclosed |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2022-12-08 | — | — | US | disclosed |
| WO-2021080646-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2021-04-29 | — | — | WO | disclosed |
| US-20200163961-A1 | Bicyclic Compounds and Methods for Their Use in Treating Autistic Disorder and Autism | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2020-05-28 | — | — | US | disclosed |
| US-10548892-B2 | Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2020-02-04 | — | — | US | disclosed |
| US-20180140601-A1 | Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2018-05-24 | — | — | US | disclosed |
| US-20180140601-A1 | Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2018-05-24 | — | — | US | disclosed |
| US-9867823-B2 | Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2018-01-16 | — | — | US | disclosed |
| US-20110201614-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-08-18 | — | — | US | disclosed |
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-03-03 | — | — | US | disclosed |
| US-7776876-B2 | Cyclic G-2Allylproline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS, LTD. (NZ) | 2010-08-17 | — | — | US | disclosed |
| US-7776876-B2 | Cyclic G-2Allylproline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS, LTD. (NZ) | 2010-08-17 | — | — | US | disclosed |
| US-20090263334-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | BICKERDIKE MIKE JOHN | 2009-10-22 | — | — | US | disclosed |
| WO-2008063311-A2 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-08-23 | — | — | US | disclosed |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-16 | — | — | US | disclosed |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-16 | — | — | US | disclosed |
| WO-2005023815-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | PMP22, IAPP, GCG | MEN1 2803/4885ALDH1A1 3920/4885TSHR 3733/4885 |
| US-20110201614-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | GRIA2, QPCT, GRM2 | MEN1 3438/4885ALDH1A1 1796/4885TSHR 4186/4885 |
| US-20180140601-A1 | Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders | GRIN2C, GRIN2D, GRIN2A | MEN1 4135/4885ALDH1A1 1075/4885TSHR 4599/4885 |
| US-10548892-B2 | Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | GRIN2C, GRIN2D, GRIA2 | MEN1 4142/4885ALDH1A1 1322/4885TSHR 4591/4885 |
| US-20090263334-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | GRIA2, QPCT, GRM2 | MEN1 3438/4885ALDH1A1 1796/4885TSHR 4186/4885 |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | MEN1 1673/4885ALDH1A1 1440/4885TSHR 4052/4885 |
| US-20220387426-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | MEN1 1673/4885ALDH1A1 1440/4885TSHR 4052/4885 |
| US-20200163961-A1 | Bicyclic Compounds and Methods for Their Use in Treating Autistic Disorder and Autism | ADCYAP1R1, GRIN2C, ADCY2 | MEN1 3222/4885ALDH1A1 1206/4885TSHR 4666/4885 |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NLN, GAP43, BAD | MEN1 3255/4885ALDH1A1 1316/4885TSHR 4530/4885 |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | PARK7, ADCYAP1R1, LRRK2 | MEN1 3644/4885ALDH1A1 2502/4885TSHR 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.